A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
Abstract Background Agonistic monoclonal antibodies targeting 4-1BB/CD137 have shown preclinical promise, but their clinical development has been limited by severe liver toxicity or limited efficacy. Therefore, a safe and efficient immunostimulatory molecule is urgently needed for cancer immunothera...
Saved in:
| Main Authors: | Da-yan Zhang, Zhi-hua Zhang, Wen-ting Liu, Wei-ming Zhou, Peng-fei Zhou, Juan-juan Wei, Xue-jing Dai, Xiao-li Zeng, Yu-qiong Zhou, Han-wang Li, Heng Zhang, Ao-lin Shen, Lian-sheng Cheng, Guo-dong Shen, Yi-fu He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06107-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
4-1BB Antibodies in Oncology Clinical Trials: A Review
by: Robin Schwartz, et al.
Published: (2025-03-01) -
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01) -
Advances in the use of nanomicelles to enhance the efficacy of antitumour substances (review)
by: E. V. Sanarova, et al.
Published: (2025-06-01) -
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy
by: Pengchao Zhang, et al.
Published: (2025-03-01) -
Insights into the role of MSLN-positive circulating tumor cell as an auxiliary diagnostic biomarker in epithelial ovarian cancer
by: Hang Xu, et al.
Published: (2025-07-01)